Demonstrating value has become one of the biggest challenges facing life sciences companies, as payers and health technology ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

New York's attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

As part of its mission to make a dent in the sizable presbyopia market, Lenz Therapeutics has scoped out a star-studded ...

While Fujifilm has deep roots in the life sciences industry through its history working with X-ray film and diagnostic ...